Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Income from Non-Controlling Interests (2021 - 2023)

Historic Income from Non-Controlling Interests for ProQR Therapeutics (PRQR) over the last 3 years, with Q3 2023 value amounting to $315691.2.

  • ProQR Therapeutics' Income from Non-Controlling Interests rose 213643.22% to $315691.2 in Q3 2023 from the same period last year, while for Dec 2023 it was $416834.7, marking a year-over-year increase of 7841.84%. This contributed to the annual value of $415379.6 for FY2023, which is 8506.19% up from last year.
  • According to the latest figures from Q3 2023, ProQR Therapeutics' Income from Non-Controlling Interests is $315691.2, which was up 213643.22% from $17422.8 recorded in Q2 2023.
  • Over the past 5 years, ProQR Therapeutics' Income from Non-Controlling Interests peaked at $315691.2 during Q3 2023, and registered a low of -$25944.3 during Q3 2021.
  • In the last 3 years, ProQR Therapeutics' Income from Non-Controlling Interests had a median value of -$3060.7 in 2022 and averaged $52825.8.
  • Per our database at Business Quant, ProQR Therapeutics' Income from Non-Controlling Interests soared by 284678.55% in 2022 and then tumbled by 9247.56% in 2023.
  • Quarter analysis of 3 years shows ProQR Therapeutics' Income from Non-Controlling Interests stood at -$21735.5 in 2021, then soared by 85.92% to -$3060.7 in 2022, then surged by 10414.21% to $315691.2 in 2023.
  • Its Income from Non-Controlling Interests was $315691.2 in Q3 2023, compared to $17422.8 in Q2 2023 and $83720.7 in Q1 2023.